- Home
- TUYA vs CVAC Comparison
TUYA vs CVAC Comparison
Compare TUYA & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TUYA
- CVAC
- Stock Information
- Founded
- TUYA 2014
- CVAC 2000
- Country
- TUYA China
- CVAC Germany
- Employees
- TUYA N/A
- CVAC N/A
- Industry
- TUYA Computer Software: Prepackaged Software
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- TUYA Technology
- CVAC Health Care
- Exchange
- TUYA Nasdaq
- CVAC Nasdaq
- Market Cap
- TUYA 1.4B
- CVAC 1.2B
- IPO Year
- TUYA 2021
- CVAC 2020
- Fundamental
- Price
- TUYA $2.52
- CVAC $5.39
- Analyst Decision
- TUYA Strong Buy
- CVAC Hold
- Analyst Count
- TUYA 1
- CVAC 3
- Target Price
- TUYA $3.49
- CVAC $6.83
- AVG Volume (30 Days)
- TUYA 1.9M
- CVAC 619.8K
- Earning Date
- TUYA 08-26-2025
- CVAC 08-15-2025
- Dividend Yield
- TUYA 4.27%
- CVAC N/A
- EPS Growth
- TUYA N/A
- CVAC N/A
- EPS
- TUYA 0.05
- CVAC 1.01
- Revenue
- TUYA $318,493,000.00
- CVAC $599,540,810.00
- Revenue This Year
- TUYA $11.71
- CVAC N/A
- Revenue Next Year
- TUYA $12.86
- CVAC $24.04
- P/E Ratio
- TUYA $51.13
- CVAC $5.37
- Revenue Growth
- TUYA 22.29
- CVAC 675.15
- 52 Week Low
- TUYA $1.28
- CVAC $2.37
- 52 Week High
- TUYA $4.63
- CVAC $5.72
- Technical
- Relative Strength Index (RSI)
- TUYA 50.47
- CVAC 49.09
- Support Level
- TUYA $2.46
- CVAC $5.33
- Resistance Level
- TUYA $2.88
- CVAC $5.48
- Average True Range (ATR)
- TUYA 0.12
- CVAC 0.04
- MACD
- TUYA 0.00
- CVAC -0.01
- Stochastic Oscillator
- TUYA 37.93
- CVAC 38.89
About TUYA Tuya Inc. each representing one
Tuya Inc is an IoT cloud development platform with a mission to build an IoT developer ecosystem and enable everything to be smart. The Company has pioneered a purpose-built IoT cloud development platform that delivers a full suite of offerings, including platform-as-a-service (PaaS) and Software-as-a-service (SaaS), to businesses and developers. Through its IoT cloud development platform, it has enabled developers to activate a vibrant IoT ecosystem of brands, OEMs, partners, and end users to engage and communicate through a broad range of smart devices. The company's revenue is derived from the PRC.
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.